Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Last updated May 15, 2015
Status:
Concluded with an LOI
Manufacturer:
Biocodex SA
Indication:
Dravet Syndrome (DS)
Last updated May 11, 2015
Anoro Ellipta (umeclidinium/vilanterol)
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Chronic Obstructive Pulmonary Disease (COPD)
Last updated May 1, 2015
Signifor (pasireotide diaspartate)
Status:
Negotiations were not pursued
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Cushing's disease
Last updated April 30, 2015
Status:
Concluded with an LOI
Manufacturer:
EMD Serono Canada, a division of EMD Inc.
Indication:
Clinically Isolated Syndrome
Last updated April 21, 2015
Ultibro Breezhaler (indacaterol/glycopyrronium)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Chronic Obstructive Pulmonary Disease (COPD)
Last updated April 20, 2015
Status:
Concluded with an LOI
Manufacturer:
Astellas Pharma Inc.
Indication:
Overactive Bladder
Last updated April 8, 2015
Status:
Concluded with an LOI
Manufacturer:
ViiV Healthcare
Indication:
HIV-1 Infection
Last updated April 8, 2015
Triumeq (dolutegravir/abacavir/lamivudine)
Status:
Concluded with an LOI
Manufacturer:
ViiV Healthcare
Indication:
HIV-1 Infection
Last updated April 8, 2015
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Post myocardial infarction
Last updated March 31, 2015